BioVersys

In the context of the transition of the accounting and reporting standard to IFRS, IFBC was engaged by BioVersys to value the employee stock options issued in the past, considering the requirements of IFRS 2 and best practice. The results were summarized in a valuation report for the attention of the auditors. BioVersys AG is a Swiss clinical stage biotechnology firm, focusing on research and development in the field of drug-resistant bacterial infections.